window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'UA-108383172-1');

Novigenix awarded EUR 1.8M in the groundbreaking BRECISE IHI Consortium to industrialize AI-powered liquid biopsy for prediction of immunotherapy response

By |2025-03-31T16:06:12+02:0031 March 2025|Communiqué de presse, Communiqué de presse, Communiqué de presse, Communiqué de presse, News Novigenix, News Novigenix, News Novigenix|

Lausanne, Switzerland, March 31, 2025 – Novigenix, a leader in AI-driven precision liquid biopsy solutions, has been awarded EUR 1.8M through the new BRECISE IHI grant funded by the European Union (EU) research initiative focusing on revolutionizing cancer diagnostics, treatment, and monitoring through advanced multi-omics and artificial intelligence. The BRECISE consortium was launched last

New study reveals novel multi-omics approach with unprecedented treatment response prediction in metastatic urothelial cancer

By |2025-03-11T15:39:20+02:0011 March 2025|Communiqué de presse, Communiqué de presse, Communiqué de presse, Communiqué de presse, News Novigenix, News Novigenix, News Novigenix|

Lausanne, Switzerland, March 11, 2025 - Novigenix, a leader in AI-driven healthcare solutions, has published a groundbreaking study showcasing the predictive power of its LITOSeek™ platform for immunotherapy response in metastatic urothelial cancer.  The study titled, “Multimodal Integration of Blood RNA and ctDNA Reflects Response to Immunotherapy in Metastatic Urothelial Cancer” [link], has been

Breakthrough study reveals blood transcriptomic alternations for early detection of colorectal cancer

By |2024-11-28T09:45:24+02:0027 November 2024|Communiqué de presse, Communiqué de presse, Communiqué de presse, Communiqué de presse, News Novigenix, News Novigenix, News Novigenix|

Lausanne, Switzerland, November 25, 2024 – Novigenix, a leader in AI-driven healthcare solutions, has published a new study marking a significant milestone in advancing early colorectal cancer (CRC) detection through innovative immune system profiling. The groundbreaking research, “Human blood cell transcriptomics unveils dynamic systemic immune modulation along colorectal cancer progression,” [link] has been published in the Journal for Immunotherapy of Cancer.

Understanding Tumor Immunology: How AI-powered blood RNA analysis could unlock immunotherapy prognoses

By |2024-10-17T14:04:25+02:0017 October 2024|Communiqué de presse, Communiqué de presse, Communiqué de presse, Communiqué de presse, News Novigenix, News Novigenix, News Novigenix|

By Pedro Romero, Chief Medical & Scientific Officer of Novigenix - Identifying markers in body fluids via liquid biopsy holds great promise for detecting diseases (such as cancer) at early stages, following disease progression and population heterogeneity, and, importantly, predicting a response to therapy with minimal patient inconvenience. Liquid biopsy relies on easy access

Prostate cancer breakthrough: Novigenix-led project receives €1.75M grant to improve patient outcomes using liquid biopsy technology

By |2024-09-24T10:25:34+02:0024 September 2024|Communiqué de presse, Communiqué de presse, Communiqué de presse, Communiqué de presse, News Novigenix, News Novigenix, News Novigenix|

Lausanne, Switzerland, September 24, 2024 – Groundbreaking funding promises to revolutionize care for patients with advanced prostate cancer by addressing treatment resistance through innovative liquid biopsy technology. Novigenix, a leader in AI-driven healthcare solutions, has today announced the approval of a Eurostars grant for the MYeloid SIGNATUREs (MY-SIGNATURE) project. This prestigious grant, totaling a

Novigenix unveils multimodal liquid biopsy approach at ESMO 2024, advancing precision medicine with AI-powered immune profiling

By |2024-09-12T14:42:16+02:0012 September 2024|Communiqué de presse, Communiqué de presse, Communiqué de presse, Communiqué de presse, News Novigenix, News Novigenix, News Novigenix|

Lausanne, Switzerland, September 12, 2024 – Novigenix, an innovator in precision medicine and liquid biopsy technologies, will showcase its multimodal approach at the European Society for Medical Oncology (ESMO) 2024 conference. This is poised to revolutionize the landscape of oncology treatment and drug development. The new approach combines advanced immune profiling with cell-free DNA (cfDNA) analysis, providing

Novigenix receives ISO 13485 Certification from BSI

By |2024-09-11T13:56:37+02:0011 September 2024|Communiqué de presse, Communiqué de presse, Communiqué de presse, Communiqué de presse, News Novigenix, News Novigenix, News Novigenix|

Geneva, September 11, 2024 - Novigenix, a leader in AI-driven healthcare solutions, successfully achieved ISO 13485:2016 certification, passing the Stage II audit with zero non-conformities. This milestone underscores Novigenix's unwavering commitment to the highest standards of quality in providing solutions for the biopharma industry. ISO 13485:2016 is an internationally recognized standard for quality management systems

Novigenix honored as Best 2024 Technology Innovation in oncology by MATWIN Board

By |2024-05-30T12:31:57+02:0029 May 2024|Communiqué de presse, Communiqué de presse, Communiqué de presse, Communiqué de presse, News Novigenix, News Novigenix, News Novigenix|

Lausanne, May 29, 2024 – Novigenix, a leader in AI-driven healthcare solutions, has been awarded the prestigious recognition of 'Best 2024 Technology Innovation' in oncology by the MATWIN Board, the premier European convention dedicated to innovation in cancer treatment. This recognition highlights Novigenix's groundbreaking contributions to personalized cancer care and its commitment to advancing

Revolutionizing Colorectal Cancer Screening with Novigenix Innovations

By |2024-06-17T20:38:04+02:0027 May 2024|Communiqué de presse, Communiqué de presse, Communiqué de presse, Communiqué de presse, News Novigenix, News Novigenix, News Novigenix|

Recent research in the New England Journal of Medicine highlights significant advances in colorectal cancer (CRC) screening. Novigenix leads this innovation with our unique approach that combines liquid biopsy, AI, and RNA analysis, promising a transformative impact on early cancer detection. Colorectal cancer is a major global health concern, projected to rise by 63%

Novigenix and IMMUcan forge a transformative partnership in AI-driven immunotherapy advancements

By |2024-05-24T15:24:35+02:004 April 2024|Communiqué de presse, Communiqué de presse, Communiqué de presse, Communiqué de presse, News Novigenix, News Novigenix, News Novigenix|

04.04.2024, Geneva - In a significant step forward for personalized cancer care, Novigenix, a pioneer in AI healthcare solutions, has been selected as a key partner by the IMMUcan consortium for the development of RNA sequencing biomarkers and to advance the understanding of the immune system's response to checkpoint inhibitors in cancer patients. IMMUcan consortium

Go to Top